Avalon Investment & Advisory Ligand Pharmaceuticals Inc Transaction History

Avalon Investment & Advisory

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 14, 2019	SELL	$128.36 - $272.13 $1.76 Million - $3.74 Million	-13,742 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$211.18 - $274.49 $205,266 - $266,804	972 Added 7.61%	13,742 $3.77 Million
Q2 2018 Aug 14, 2018	BUY	$150.77 - $207.98 $173,837 - $239,800	1,153 Added 9.93%	12,770 $2.65 Million
Q1 2018 Jun 26, 2018	SELL	$138.63 - $182.62 $277 - $365	-2 Reduced 0.02%	11,617 $1.92 Million
Q1 2018 May 15, 2018	BUY	$138.63 - $182.62 $1.61 Million - $2.12 Million	11,619 New	11,619 $1.92 Million

257

18.2M

26.8K

9.3K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $2.01B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of Avalon Investment & Advisory, based on Form 13F filings with the SEC.

Stay updated on Avalon Investment & Advisory with notifications on news.